|
1
|
Greenberg D, Earle C, Fang CH,
Eldar-Lissai A and Neumann PJ: When is cancer care cost-effective?
A systematic overview of cost-utility analyses in oncology. J Natl
Cancer Inst. 102:82–88. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huang C, Liang J, Ma M, Cheng Q, Xu X,
Zhang D, Shi C, Shang N, Xiao Z and Luo L: Evaluating the treatment
efficacy of nano-drug in a lung cancer model using advanced
functional magnetic resonance imaging. Front Oncol.
10(563932)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zheng W, Zhang Y, Guo L, Wang S, Fang M,
Mao W and Lou J: Evaluation of therapeutic efficacy with
CytoSorter((R)) circulating tumor cell-capture system in patients
with locally advanced head and neck squamous cell carcinoma. Cancer
Manag Res. 11:5857–5869. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kashkooli FM and Soltani M: Evaluation of
solid tumor response to sequential treatment cycles via a new
computational hybrid approach. Sci Rep. 11(21475)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cherla A, Renwick M, Jha A and Mossialos
E: Cost-effectiveness of cancer drugs: Comparative analysis of the
United States and England. EClinicalMedicine.
29-30(100625)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kang R, Goodney PP and Wong SL: Importance
of cost-effectiveness and value in cancer care and healthcare
policy. J Surg Oncol. 114:275–280. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li J and Luo W: Hospitalization expenses
of acute ischemic stroke patients with atrial fibrillation relative
to those with normal sinus rhythm. J Med Eco. 20:114–120.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ding JM, Zhang XZ, Hu XJ, Chen HL and Yu
M: Analysis of hospitalization expenditures and influencing factors
for inpatients with coronary heart disease in a tier-3 hospital in
Xi'an, China: A retrospective study. Medicine (Baltimore).
96(e9341)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li Y, Li J, Li B, Zhang L, Zeng Z and Zeng
W: An evaluation index system for research efficiency of
research-oriented hospitals in China. Inquiry.
58(469580211059469)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou X, Ding P, Yang Q, Wang P, Zhou H, Fu
J and Miao D: Construction of an index system for evaluating the
effectiveness of transitional care in kidney transplant recipients.
BMC Med Inform Decis Mak. 21(132)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pourrajab F, Zare-Khormizi MR, Hashemi AS
and Hekmatimoghaddam S: Genetic characterization and risk
stratification of acute myeloid leukemia. Cancer Manag Res.
12:2231–2253. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kirchner JE, Smith JL, Powell BJ, Waltz TJ
and Proctor EK: Getting a clinical innovation into practice: An
introduction to implementation strategies. Psychiatry Res.
283(112467)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bose P, Vachhani P and Cortes JE:
Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat
Opt Oncol. 18(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Allen CE, Merad M and McClain KL:
Langerhans-cell histiocytosis. N Engl J Med. 379:856–868.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gupta AK, Meena JP, Chopra A, Tanwar P and
Seth R: Juvenile myelomonocytic leukemia-A comprehensive review and
recent advances in management. Am J Blood Res. 11:1–21.
2021.PubMed/NCBI
|
|
17
|
Ranganathan P and Aggarwal R: Study
designs: Part 1-An overview and classification. Perspect Clin Res.
9:184–186. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Euser AM, Zoccali C, Jager KJ and Dekker
FW: Cohort studies: Prospective versus Retrospective. Nephron Clin
Pract. 113:c214–c217. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Talari K and Goyal M: Retrospective
studies-utility and caveats. J R Coll Physic Edinb. 50:398–402.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wu Z, Wu Z, Zou Y, Guan J, Wu S and Chen
D: A clinical report on high-dose cytarabine therapy for children
with acute myeloid leukemia. Mol Clin Oncol. 17(156)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Asaria M, Griffin S, Cookson R, Whyte S
and Tappenden P: Distributional cost-effectiveness analysis of
health care programmes-a methodological case study of the UK Bowel
Cancer Screening Programme. Health Eco. 24:742–754. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Karády J, Mayrhofer T, Ivanov A, Foldyna
B, Lu MT, Ferencik M, Pursnani A, Salerno M, Udelson JE, Mark DB,
et al: Cost-effectiveness analysis of anatomic vs functional index
testing in patients with low-risk stable chest pain. JAMA Netw
Open. 3(e2028312)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pandya BJ, Chen CC, Medeiros BC, McGuiness
CB, Wilson SD, Walsh EH and Wade RL: Economic and clinical burden
of acute myeloid leukemia episodes of care in the United States: A
retrospective analysis of a commercial payer database. J Manag Care
Spec Pharm. 26:849–859. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing
RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, et al:
Comparison of in-patient costs for children treated on the AAML0531
clinical trial: A report from the children's oncology group.
Pediatr Blood Cancer. 62:1775–1781. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
John MJ, Kuriakose P, Smith M, Roman E and
Tauro S: The long shadow of socioeconomic deprivation over the
modern management of acute myeloid leukemia: time to unravel the
challenges. Blood Cancer J. 11(141)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Al-Badriyeh D, Alameri M and Al-Okka R:
Cost-effectiveness research in cancer therapy: A systematic review
of literature trends, methods and the influence of funding. BMJ
Open. 7(e012648)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Maruvka YE, Tang M and Michor F: On the
validity of using increases in 5-year survival rates to measure
success in the fight against cancer. PLoS One.
9(e83100)2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hofmarcher T, Lindgren P, Wilking N and
Jönsson B: The cost of cancer in Europe 2018. Eur J Cancer.
129:41–49. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tsimberidou AM, Fountzilas E, Nikanjam M
and Kurzrock R: Review of precision cancer medicine: Evolution of
the treatment paradigm. Cancer Treat Rev. 86(102019)2020.PubMed/NCBI View Article : Google Scholar
|
